Y-mAbs Therapeutics Inc.
750 Third Avenue, 9th Floor
About Y-mAbs Therapeutics Inc.YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7-H3. To further improve our bispecific antibodies, we are collaborating with MSK on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.
Founder, President and Head of Business Development and Strategy: Thomas Gad
CEO: Claus Moller
CFO: Bo Kruse
SVP, Head of Technical Operations: Torben Lund-Hansen, PhD
SVP, CMO: Ole Baadsgaard, MD, DMSc
Please click here for YmAbs' job opportunities.
6 articles with Y-mAbs Therapeutics Inc.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
MabVax Therapeutics Holdings, Inc. has granted to Y-mAbs Therapeutics, Inc., an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma
Together, with the $50 million raised in the first closing, the Company has now raised $80 million pursuant to this private placement round.
10/24/2017The cash enables YmAbs to focus on bringing the company's lead compound through the final steps of the regulatory pathway towards approval.